VassilikiPapadimitrakopoulouMD

Oncology • Houston, TX

Head & Neck Cancer

Professor of Medicine, University Tex Houston

Join to view full profile

Dr. Papadimitrakopoulou is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Papadimitrakopoulou's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1992 - 1994
Icahn School of Medicine at Mount Sinai/Morningside/WestInternship, Internal Medicine, 1991 - 1992
University of Patras School of MedicineClass of 1990

Certifications & Licensure

TX State Medical License 1997 - 2025

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

BMS-214662 in Treating Patients With Solid Tumors Start of enrollment: 2000 Apr 01
Completed
Phase 1
Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer Start of enrollment: 2006 Apr 01
Completed
Phase 2
Erlotinib Prevention of Oral Cancer (EPOC) Start of enrollment: 2006 Nov 03
Completed
Phase 3
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2011 Jun 02
Completed
Phase 2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2014 Jul 31
Completed
Phase 2, Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Oct 01
Completed
Phase 2, Phase 3
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer Start of enrollment: 2017 Nov 30
Completed
Phase 2
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2017 Mar 03
Completed
Phase 2
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer Start of enrollment: 2019 Feb 06
Recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2024-11-01
Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Jacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, Brett W Carter, Shuxing Zhang
Nature Medicine. 2024-09-01
15 citations
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analy...
Jhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, Frances A Shepherd, Fumio Imamura
Clinical Cancer Research. 2023-09-01

Journal Articles

Landscape of EGFR -Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Post-Progression in EGFR-Mutant NSCLC
Stephen G Swisher, Vassiliki A Papadimitrakopoulou, John V Heymach, Jack A Roth, Jianjun Zhang, William N William, Bonnie S Glisson, Clinical Cancer Research
JAK1/STAT3 Activation Through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer
John D Minna, Jonathan M Kurie, J Jack Lee, Vassiliki A Papadimitrakopoulou, Neda Kalhor, Roy S Herbst, Clinical Cancer Research
Validation of the 12-Gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer
Cesar Moran, Jack A Roth, Yang Xie, John D Minna, Vassiliki A Papadimitrakopoulou, John V Heymach, Stephen G Swisher, Clinical Cancer Research

Lectures

Future of Novel Agents for Squamous Cell Carcinoma: Lung-MAP Trial
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protoc...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Chutes & Ladders—Bayer Trims 2 Execs in Corporate ReshufflingSeptember 13th, 2019
Pfizer Hires Ex-FDA, MD Anderson Researcher as Clinical Oncology LeadSeptember 11th, 2019
#News #Biotech Pfizer Hires Ex-FDA, MD Anderson Researcher as Clinical Oncology LeadSeptember 11th, 2019
Join now to see all